Limited long-term efficacy of intravitreous anti-VEGF pharmacotherapy in sarcoidosis complicated by peripapillary choroidal neovascular membrane.
Shah
Sumit P
SP
Hubschman
Jean-Pierre
JP
Bourges
Jean-Louis
JL
Hu
Allen Y H
AY
Schwartz
Steven D
SD
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D017075:Laser Coagulation; D008297:Male; D008875:Middle Aged; D015864:Panuveitis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D000069579:Ranibizumab; D012008:Recurrence; D012507:Sarcoidosis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab